Latest News

Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...

The recent U.S. FDA draft guidance endorsing minimal residual disease and complete response as endpoints in multiple myeloma, together with new 2026 Tandem Meetings data, has drawn fresh attention to Arcellx (ACLX) and its lead CAR T program. See our latest analysis for Arcellx. After the FDA draft guidance and the new 2026 Tandem Meetings data, Arcellx’s recent 5.66% 1 month share price return stands against an 18.08% 3 month share price decline and a very large 3 year total shareholder...

Novavax (NasdaqGS:NVAX) has signed a licensing agreement with Pfizer covering the use of its Matrix-M adjuvant technology in up to two infectious disease areas. The deal includes upfront payments to Novavax, with the potential for future milestone payments and royalties tied to Pfizer’s use of Matrix-M. The agreement signals industry interest in Novavax’s adjuvant platform and introduces new potential revenue channels alongside its own vaccine programs. For you as an investor, this puts...

If you are wondering whether Mitsui's current share price fairly reflects the business, you are not alone. This article will walk you through what the numbers are really saying about value. Mitsui's share price recently closed at ¥5,133, with returns of 11.6% over 30 days, 8.0% year to date, 73.3% over 1 year, 188.4% over 3 years and a very large gain over 5 years. That naturally raises questions about how much potential or risk is already priced in. Recent coverage has focused on Mitsui's...

Updated guidance shifts attention to Vericel Vericel (VCEL) has put out preliminary unaudited guidance for the fourth quarter and full year 2025, flagging 23% revenue growth for the quarter and an expected US$276 million in net revenue for the year. The company also anticipates GAAP net income profitability for a second straight year, a detail many investors watch closely when considering how a commercial stage biotech is converting its product portfolio into earnings. See our latest analysis...

Key Insights The considerable ownership by retail investors in Taiyo Holdings indicates that they collectively have a...

Zoetis (NYSE:ZTS) has launched new next generation osteoarthritis treatments, Lenivia and Portela. The products are designed to address safety concerns linked to earlier osteoarthritis pain drugs Librela and Solensia. Both treatments are long acting and require less frequent administration, targeting continuity of care and market share in osteoarthritis pain management. Zoetis, a major animal health company, is expanding its osteoarthritis portfolio with Lenivia and Portela, which aim to...

Array Technologies (NasdaqGM:ARRY) saw renewed investor interest after the US president announced a framework for a future deal with Greenland, easing some global trade tensions. The shift in sentiment is tied to expectations around cross border trade in renewable energy equipment and policy stability. Array’s shares last closed at $10.22 as investors reassessed exposure to companies linked to global solar and clean energy supply chains. Array Technologies comes into this news with a mixed...

Recent projections for stronger earnings and revenue at Bank of Hawaii have lifted sentiment across Hawaiian regional banks, and you are now seeing that readthrough show up in First Hawaiian (FHB) as investor interest picks up. See our latest analysis for First Hawaiian. That positive readthrough from Bank of Hawaii comes on top of a steady upswing in First Hawaiian’s own trading, with a 1-day share price return of 4.59% and a 90-day share price return of 17.05%. The 5-year total shareholder...

Alphamin Resources (TSXV:AFM) is back in focus after reporting record 2025 tin production of 18,576 tonnes, issuing 2026 guidance of about 20,000 tonnes, and outlining a CEO and CFO transition from March 2026. See our latest analysis for Alphamin Resources. The record 2025 tin output, higher 2026 production guidance and the announced CEO and CFO transition sit alongside a 1 month share price return of 11.67% and a year to date share price return of 15.52%, while the 1 year total shareholder...

TUM Klinikum Rechts der Isar’s decision to expand its Sectra (OM:SECT B) enterprise imaging setup with new pathology and ophthalmology modules puts fresh attention on how this five year contract fits into the stock’s current performance. See our latest analysis for Sectra. The TUM Klinikum Rechts der Isar contract lands at a time when Sectra’s share price, now at SEK 224.6, has a 30 day share price return of a 10.87% decline and a 90 day share price return of a 27.45% decline. Meanwhile, the...

Allegations of systemic predatory sales practices at LGI Homes (NasdaqGS:LGIH) have surfaced, focusing on pressure tactics used on vulnerable homebuyers. The company is accused of providing unlicensed mortgage advice and steering customers toward affiliated lenders, which may conflict with consumer protection rules. Questions are being raised about potential breaches of privacy obligations and how any regulatory response could affect LGI Homes' operations and brand. LGI Homes builds and...

We didn't see Kawasaki Geological Engineering Co., Ltd.'s ( TSE:4673 ) stock surge when it reported robust earnings...

Key Insights Significant control over HD Korea Shipbuilding & Offshore Engineering by retail investors implies that the...

In January 2026, Kesko Corporation reported that its group sales excluding VAT reached €1,060.5 million for December 2025, €3,314.5 million for the fourth quarter, and €12.77 billion for the full year, all showing year-on-year growth. The simultaneous acceleration in monthly, quarterly, and annual sales highlights broad-based momentum across Kesko’s operations rather than a one-off seasonal effect. Next, we will examine how this broad-based sales growth shapes Kesko’s investment narrative...

ASML Holding (NasdaqGS:ASML) is again in focus as attention turns to its exclusive role as the only producer of extreme ultraviolet (EUV) lithography systems. The company’s lack of credible competition in EUV tools is being highlighted as a key feature of its current position in advanced chip manufacturing equipment. Global peers are still viewed as unable to match ASML’s EUV capability, reinforcing the discussion around its monopoly like status in this niche. ASML sits at the center of the...

Banco Bilbao Vizcaya Argentaria (BME:BBVA) has launched a new share buyback program. The buyback is part of the bank's broader capital management approach, focusing on returning excess capital to shareholders. The program is intended to reduce the number of shares in circulation and adjust BBVA's capital structure. BBVA is a large banking group with a presence across retail, corporate, and investment banking, as well as payment and digital services. For investors, a new buyback program can...

TUI recently saw strong investor interest following reports of a steady recovery in holiday bookings and improving cash flow metrics, ahead of its scheduled earnings release on 10 February 2026. This combination of operational progress and an upcoming results catalyst has sharpened focus on how effectively TUI is converting higher demand into healthier balance sheet trends. With recent share price gains over both one and seven days, we’ll explore how improving bookings reshape TUI’s broader...

Recent performance snapshot Enovis (ENOV) has drawn attention after a 2.6% gain in the latest session, set against weak recent returns, including about a 13% decline over the past month and roughly 27% over the past 3 months. See our latest analysis for Enovis. That latest move comes after a tougher stretch, with a 1 year total shareholder return of about 49.6% decline and a 5 year total shareholder return of around 66.2% decline. This signals that recent share price momentum is still fading...

Amcor plc has completed a 1-for-5 reverse stock split, effective January 14, 2026, with shares now trading on a split-adjusted basis on the NYSE under the symbol AMCR and a new CUSIP, while its CHESS Depositary Interests continue under the symbol AMC. This corporate action, combined with recent supportive analyst commentary, highlights how Amcor is actively reshaping its capital structure while maintaining broad market visibility across key global packaging end markets. Next, we will examine...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

What is driving interest in ArcelorMittal right now? ArcelorMittal (ENXTAM:MT) is back in focus after recent commentary highlighted its push toward higher margin, lower carbon steel products, ongoing divestments of weaker assets, and supportive trade protections and demand trends in key regions. See our latest analysis for ArcelorMittal. The recent 6.36% 1 day share price return, a 21.14% 30 day share price return and a 104.69% 1 year total shareholder return suggest momentum has been...

What recent performance tells you about Intuitive Surgical (ISRG) With no single headline event setting the tone, Intuitive Surgical (ISRG) has been drawing attention largely because of its recent share performance, including a one-month return of about a 9.7% decline and a past three-month return of about a 5% decline. See our latest analysis for Intuitive Surgical. At a share price of US$523.69, Intuitive Surgical’s recent 7 day share price return of about a 4.2% decline and 30 day share...

Earlier in January 2026, Canadian Solar Inc. secured a decisive win at the US Patent Trial and Appeal Board, which invalidated all Maxeon Solar Pte. Ltd. patent claims at issue and followed the company’s completion of a US$200,000,000 convertible senior unsecured notes offering due 2031. This legal outcome highlights Canadian Solar’s dependence on an extensive intellectual property portfolio and its capacity to defend core solar and storage technologies in major markets. Next, we’ll examine...